FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...

Gilead (GILD) announced that the FDA has accepted its new drug application submissions for lenacapavir, the company’s twice-yearly injectable HIV-1 capsid inhibitor-for the prevention of HIV as ...

Gilead Sciences has won Food and Drug Administration priority review for its proposed lenacapavir twice-yearly shot to prevent HIV. Gilead on Tuesday said an FDA green light would make lenacapavir ...

HEBRON, Conn. (WTNH) — A driver has serious injuries following a rollover crash on Gilead Street in Hebron Monday, state police said. State police said just before 5 p.m. a Ford E350 was driving ...

According to the Hebron Fire Department, at around 4:48 p.m. firefighters and troopers were deployed to the scene of Gilead Street for reports of a two-car accident involving a rollover.

Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of Gilead Sciences Inc (Symbol: GILD) were yielding above the 3% mark based on its quarterly dividend ...

Headquartered in Foster City, CA, Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus (HIV). The company’s broad portfolio includes drugs for liver ...

Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% ...